Even though a human life enjoys plenty of luxuries from the get-go, we are still largely obligated to keep looking for a better avenue. This enables us big time in regards to scaling up our floor rather consistently, and when you are playing with such a progressive dynamic, the said avenues also tend to get better over time. However, the only problem is that not all of them are worth pursuing, so segregating the genuine ones from the rest becomes a really tricky task. Now, we have made some mistakes around here, but we compensated for many of them by being accurate in technology’s case. Despite not being anything like how we know it as today, technology’s early iterations still had the world excited beyond every limit. After all, we had never seen something so ingenious before. If that in itself wasn’t fascinating enough, the creation broke another mould by leaving its mark across our entire spectrum, including on a highly-critical medical sector. Technology entered the healthcare fray when the sector was literally running on fumes. Plagued by obsolete methods, it seemingly had no hope, but the stated reality will change eventually, and once it does, the sector won’t look back. This was reaffirmed yet again during a recent funding round.
Satellite Bio, a regenerative med biotech, has officially secured over $110 million in a combination of Series A and seed financing. Led by aMoon Growth, the round went on to see many other close participants, including Lightspeed, aMoon Velocity, Polaris Partners and Polaris Innovation Fund, Section 32, Catalio Capital Management and Waterman Ventures. The funding coincides with the unveil of company’s much-awaited Tissue Therapeutics, which are basically bioengineered tissue that can be used to repair, restore, or replace a critical organ and tissue function. Satellite Bio carries out the whole process through an exclusive Satellite Adaptive Tissue (SAT) platform. The company uses the platform to selectively program cells before assembling them into novel, implantable therapies. These therapies are then introduced to the patient as a way of making up for a dysfunctional organ or tissue.
“Tissue Therapeutics replaces organ and tissue systems that break down during disease progression. This next frontier of regenerative medicine has enormous potential to provide solutions for some of the most elusive diseases,” said Dave Lennon, PhD, chief executive officer of Satellite Bio. “Our SAT platform can be used with virtually any type of cell across a wide range of clinical applications, enabling the potential to create a broad pipeline of implantable Tissue Therapeutic solutions for patients.”
While regenerative medicine remains bit of a murky area for many experts, studies have shown that the bioengineered tissue-based approach can actually work under real-world circumstances. According to a study published by Science Translational Medicine, the implantation of bioengineered cells in a mouse model displayed a desired growth pattern over time, and once the procedure was completed, the artificial issue was also able to fulfill all the natural functions.
